Skip to main content
. Author manuscript; available in PMC: 2016 Jan 16.
Published in final edited form as: Nature. 2015 Jun 8;523(7560):342–346. doi: 10.1038/nature14462

Extended Data Fig 6. Treatment with the S1P1 modulator FTY720 or the S1P1- specific agonist AUY954 suppresses BrdU incorporation by LSK and CLP in Apom−/− bone marrow.

Extended Data Fig 6

Percent BrdU incorporation 24 hours post-treatment with (a) 0.5 mg/kg FTY720 or (b) 1.0 mg/kg AUY954. (a) WT, n = 4; Apom−/−, n = 5 for vehicle-treated and WT, n = 7; Apom−/−, n = 8 for FTY720-treated groups. (b) Vehicle-treated, n = 3; AUY954-treated, n = 6.. Bars represent means ± SD and data are compiled from two experiments. *p < 0.05 versus WT; §p < 0.05 versus vehicle-treated control.